scholarly journals Pathophysiology of Vascular Calcification and Bone Loss: Linked Disorders of Ageing?

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 3835
Author(s):  
Jorge B. Cannata-Andía ◽  
Natalia Carrillo-López ◽  
Osvaldo D. Messina ◽  
Neveen A. T. Hamdy ◽  
Sara Panizo ◽  
...  
Keyword(s):  
Bone Loss ◽  
Vascular Calcification ◽  
Clinical Observation ◽  
Fragility Fractures ◽  
Low Bone Mass ◽  
Active Process ◽  
Left Ventricle Hypertrophy ◽  
Age Dependent ◽  
The Common ◽  
Ventricle Hypertrophy

Vascular Calcification (VC), low bone mass and fragility fractures are frequently observed in ageing subjects. Although this clinical observation could be the mere coincidence of frequent age-dependent disorders, clinical and experimental data suggest that VC and bone loss could share pathophysiological mechanisms. Indeed, VC is an active process of calcium and phosphate precipitation that involves the transition of the vascular smooth muscle cells (VSMCs) into osteoblast-like cells. Among the molecules involved in this process, parathyroid hormone (PTH) plays a key role acting through several mechanisms which includes the regulation of the RANK/RANKL/OPG system and the Wnt/ß-catenin pathway, the main pathways for bone resorption and bone formation, respectively. Furthermore, some microRNAs have been implicated as common regulators of bone metabolism, VC, left ventricle hypertrophy and myocardial fibrosis. Elucidating the common mechanisms between ageing; VC and bone loss could help to better understand the potential effects of osteoporosis drugs on the CV system.

scholarly journals MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management

2015 ◽  
Vol 173 (3) ◽  
pp. R131-R151 ◽  
Author(s):  
Faryal Mirza ◽  
Ernesto Canalis
Keyword(s):  
Bone Loss ◽  
Fragility Fractures ◽  
Low Bone Mass ◽  
Endocrine Disease ◽  
Skeletal Fragility ◽  
Increased Risk ◽  
Common Causes ◽  
The Common ◽  
Skeletal Disorder ◽  
Underlying Mechanisms

Osteoporosis is a skeletal disorder characterized by decreased mass and compromised bone strength predisposing to an increased risk of fractures. Although idiopathic osteoporosis is the most common form of osteoporosis, secondary factors may contribute to the bone loss and increased fracture risk in patients presenting with fragility fractures or osteoporosis. Several medical conditions and medications significantly increase the risk for bone loss and skeletal fragility. This review focuses on some of the common causes of osteoporosis, addressing the underlying mechanisms, diagnostic approach and treatment of low bone mass in the presence of these conditions.

scholarly journals Effect of fosinopril on progression of the asymptomatic carotid atherosclerosis and left ventricular hypertrophy in hypertensive patients

2006 ◽  
Vol 134 (3-4) ◽  
pp. 106-113 ◽  
Author(s):  
Ivan Tasic ◽  
Dragan Mijalkovic ◽  
Dragan Djordjevic ◽  
Branko Lovic ◽  
Dimitrije Jankovic ◽  
...  
Keyword(s):  
Left Ventricle ◽  
Ace Inhibitor ◽  
Intima Media Thickness ◽  
Left Ventricle Mass ◽  
Hypertensive Patients ◽  
Left Ventricle Hypertrophy ◽  
Group A ◽  
The Common ◽  
Group B ◽  
Ventricle Hypertrophy

INTRODUCTION The cardiovascular changes (vascular structure changes, hypertrophy of the left ventricle) contribute to both the increased cardiovascular morbidity and the mortality of essential hypertension. Therefore, modern treatment strategies should not only target blood pressure (BP) reduction but also normalize cardiovascular structure and function. OBJECTIVE Aim of the study was to determine the effect of the ACE inhibitor Fosinopril on the Intima-media thickness of the common carotid artery and on the left ventricle mass after 9-month treatment of hypertensive patients. METHOD The study included 40 patients with the arterial hypertension and the left ventricle hypertrophy verified by echocardiography. The patients were randomized on A) ACE-inhibitor - Fosinopril and 6) without ACE inhibitor - atenolol, and they were followed up 9 months. The groups were not different by age, sex, and metabolic status. Color Duplex ultrasonography of the carotid arteries was performed by Acuson Sequia C236 with high-frequency linear probe of 8 MHz. The Intima-media thickness of the common carotids on the left and the right was measured in diastole at 1.5. cm from the highest point of bifurcation under maximal magnification. Using the same device, the left ventricle mass and other parameters of the left ventricle were determined in M-mode and by means of 2D image. RESULTS After 9 months, BP In both groups Was reduced In similar range (group A: systolic BP from 158 to 137 mmHg, and diastolic BP from 94 to 85 mmHg, and group B; systolic BP from 164 to 137 mmHg, and diastolic BP from 87 to 84 mmHg). The thickness of the intimomedial complex in patients using Fosinopril was decreased by 0.0278 ? 0.03 mm, while in the group of patients that did not use the ACE-inhibitor, it was increased by 0.078 ?0.13 mm. The left ventricle mass in patients using Fosinopril was decreased by 5 grams (312 ? 72 g vs. 307 ? 77 g), while in group B patients, it was increased by 15 grams (323 ? 79 g vs. 328 ? 58 g. Diastolic function expressed through relation E/A was improved minimally in the group A, while it worsened by 0.1 in the group B. After 9 months, serious cardiovascular events were recorded (one infarction of myocardium and one hospitalization due to the unstable angina pectoris) in two patients of the group A, while four patients of the group B. had serious CV events (1 cerebrovascular stroke and 3 hospitalizations due to unstable angina pectoris). CONCLUSION The results of our study showed that the application of Fosinopril in patients with the arterial hypertension and the left ventricle hypertrophy could efficiently block further progression of the intima-medial thickness of the common carotid artery, reduce the left ventricle mass, and improve. diastolic function of the left ventricle.

scholarly journals SAT0450 GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: A MULTIVARIATE LINEAR REGRESSION ANALYSIS IDENTIFYING PREDICTIVE FACTORS FOR LOW BONE MASS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1182.2-1182
Author(s):  
E. Wiebe ◽  
D. Freier ◽  
D. Huscher ◽  
R. Biesen ◽  
S. Hermann ◽  
...  
Keyword(s):  
Bone Mass ◽  
Rheumatic Diseases ◽  
Positive Association ◽  
Fragility Fractures ◽  
Life Time ◽  
Inflammatory Rheumatic Diseases ◽  
Low Bone Mass ◽  
Cross Sectional ◽  
Chronic Inflammatory Rheumatic Diseases ◽  
Prevalence Of Osteoporosis

Background:Rheumatic diseases are associated with increased systemic bone loss and fracture risk related to chronic inflammation, disease-specific, general and demographic risk factors as well as treatment with glucocorticoids (GC). Yet, there is evidence that GCs may, by adequately suppressing systemic inflammation, also have a positive effect on bone mineral density (BMD) and fracture risk1.Objectives:The purpose of this study was to investigate the prevalence of osteoporosis and fragility fractures in patients with inflammatory rheumatic diseases and to analyze the impact that treatment with GCs, other known risk factors and preventive measures have on bone health in these patients.Methods:Rh-GIOP is an ongoing prospective observational study collecting and analyzing disease- and bone-related data from patients with chronic inflammatory rheumatic diseases and psoriasis treated with GCs. In this cross-sectional analysis, we evaluated the initial visit of 1091 patients. A multivariate linear regression model with known or potentially influential factors adjusted for age and sex was used to identify predictors of BMD as measured by dual-energy X-ray absorptiometry (DXA). Multiple imputation was applied for missing baseline covariate data.Results:In the total cohort of 1091 patients (75% female of which 87.5% were postmenopausal) with a mean age of 62.1 (±13.2) years, the prevalence of osteoporosis by DXA was 21.7%, while fragility fractures have occurred in 31.2% of the study population (6.7% vertebral, 27.7% non-vertebral). Current GC therapy was common (64.9%), with a median daily dose of 5.0mg [0.0;7.5], a mean life-time total GC dose of 17.7g (±24.6), and a mean GC therapy duration of 7.8 years (±8.5). Bisphosphonates were the most commonly used anti-osteoporotic drug (12.6%).Multivariate analysis showed that BMD as expressed by the minimum T-Score at all measured sites was negatively associated with higher age, female sex and menopause as well as Denosumab and Bisphosphonate treatment. A positive association with BMD was found for body mass index as well as current and life-time (cumulative) GC dose. While comedication with proton-pump-inhibitors significantly predicted low bone mass, concomitant use of non-steroidal anti-inflammatory drugs showed a positive association with BMD. Of the measured bone-specific laboratory parameters, higher alkaline phosphatase levels were determinants of low DXA-values, while the association was positive for gamma-glutamyltransferase.BMD was neither predicted by duration of GC treatment nor by treatment with disease modifying anti-rheumatic drugs.Predictive variables for BMD differed at the respective anatomical site. While treatment with Denosumab predicted low bone mass at the lumbar spine and not at the femoral neck, the opposite was true for health assessment questionnaire (HAQ) score. Current and life-time GC-dose as well as direct sun-exposure of more than 30 minutes daily were positively associated with bone mass at the femoral sites only.Conclusion:This cross-sectional analysis of a prospective cohort study quantified the prevalence of osteoporosis and identified predictive variables of BMD in patients with rheumatic diseases.Multivariate analyses corroborated low BMD to be predicted by traditional factors like age, female sex and menopause but showed current and well as life-time GC dose to be positively associated with BMD in our cohort of patients with chronic inflammatory rheumatic diseases. This suggests that optimal management of disease activity with GCs might be beneficial in order to avoid bone loss due to inflammation.References:[1]Güler-Yüksel et al. “Glucocorticoids, Inflammation and Bone.” Calcified Tissue International (January 08 2018).Disclosure of Interests:Edgar Wiebe: None declared, Desiree Freier: None declared, Dörte Huscher: None declared, Robert Biesen: None declared, Sandra Hermann: None declared, Frank Buttgereit Grant/research support from: Amgen, BMS, Celgene, Generic Assays, GSK, Hexal, Horizon, Lilly, medac, Mundipharma, Novartis, Pfizer, Roche, and Sanofi.

scholarly journals The Dual Role of Vitamin K2 in “Bone-Vascular Crosstalk”: Opposite Effects on Bone Loss and Vascular Calcification

Nutrients ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 1222
Author(s):  
Domitilla Mandatori ◽  
Letizia Pelusi ◽  
Valeria Schiavone ◽  
Caterina Pipino ◽  
Natalia Di Pietro ◽  
...  
Keyword(s):  
Bone Loss ◽  
Vascular Calcification ◽  
Vascular System ◽  
The Elderly ◽  
Food Supplement ◽  
Vitamin K2 ◽  
Bioactive Molecules ◽  
Calcium Deposition ◽  
Age Related

Osteoporosis (OP) and vascular calcification (VC) represent relevant health problems that frequently coexist in the elderly population. Traditionally, they have been considered independent processes, and mainly age-related. However, an increasing number of studies have reported their possible direct correlation, commonly defined as “bone-vascular crosstalk”. Vitamin K2 (VitK2), a family of several natural isoforms also known as menaquinones (MK), has recently received particular attention for its role in maintaining calcium homeostasis. In particular, VitK2 deficiency seems to be responsible of the so-called “calcium paradox” phenomenon, characterized by low calcium deposition in the bone and its accumulation in the vessel wall. Since these events may have important clinical consequences, and the role of VitK2 in bone-vascular crosstalk has only partially been explained, this review focuses on its effects on the bone and vascular system by providing a more recent literature update. Overall, the findings reported here propose the VitK2 family as natural bioactive molecules that could be able to play an important role in the prevention of bone loss and vascular calcification, thus encouraging further in-depth studies to achieve its use as a dietary food supplement.

Loss of milk fat globule-epidermal growth factor 8 (MFG-E8) in mice leads to low bone mass and accelerates ovariectomy-associated bone loss by increasing osteoclastogenesis

Bone ◽  
2015 ◽  
Vol 76 ◽  
pp. 107-114 ◽  
Author(s):  
Kathrin Sinningen ◽  
Elise Albus ◽  
Sylvia Thiele ◽  
Sylvia Grossklaus ◽  
Thomas Kurth ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Bone Loss ◽  
Bone Mass ◽  
Milk Fat ◽  
Low Bone Mass ◽  
Milk Fat Globule ◽  
Epidermal Growth ◽  
Fat Globule

Twinning in Susceptible Mothers—An Exploratory Study of International Data by Payami's Models Suggests “Reproductive Maturity” as a Risk Factor

1991 ◽  
Vol 40 (3-4) ◽  
pp. 269-289 ◽  
Author(s):  
P. Philippe
Keyword(s):  
Maternal Age ◽  
Comparison Group ◽  
Linear Increase ◽  
Reproductive Maturity ◽  
Secondary Exposure ◽  
Twin Birth ◽  
Age Dependent ◽  
Common Etiology ◽  
International Data ◽  
The Common

AbstractAn attempt has been made to apply Payami's models to maternal age-specific twin birth prevalences in several countries. The models disclose the heterogeneity of a cohort and spell out the risks to susceptible members (who will actually get the disease) according to age (or time). Payami's method specifies that the typical cohort of susceptibles is ascribed to two exposures: a potent and generalised exposure and a very low or no risk secondary exposure. The models have been adjusted to international data from current as well as old populations, of Occidental and Japanese origin. Results show that cohorts of twin-prone mothers aged 25 to 45 are homogeneous. A single dominant etiology is suggested which applies to both MZ and DZ twins. Heterogeneity, from 10% to 25%, is present in all countries whenever the 20-24 age group is involved. A separate study of illegitimate twin births from Denmark reduces the heterogeneity and shows that MZ illegitimate twin births are due to a secondary exposure responsible for a distinct twinning etiology. The age-specific risks of a MZ illegitimate twin birth are much higher than those of any comparison group, and are constant until age 35 years. This suggests a single-hit exposure akin to a neuroendocrine stimulus which short-cuts the usual age-dependent etiologic pathway. MZ and DZ twins both experience the same maternal age specific risks, an observation which underscores the common etiology of both types of twins. Risks increase with age from age 20 to 45 years. The pattern according to age varies among countries and time periods. Occidental populations have a pattern varying from an exponential to a more linear increase in old and recent populations, respectively. Only present-day Japan displays a logarithmic-like growth curve. The concept of “reproductive maturity” is introduced, and related to the secular trend of the DZ twin birth risk and to its variation across countries. Two new conclusions are drawn: a) The higher the rate of reproductive maturity, the less the DZ twin birth risk and, b) Reproductive maturity determines the maternal age-specific gonadotropin levels.

scholarly journals Alendronate as an Effective Treatment for Bone Loss and Vascular Calcification in Kidney Transplant Recipients

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Masanori Okamoto ◽  
Shintaro Yamanaka ◽  
Wataru Yoshimoto ◽  
Takashi Shigematsu
Keyword(s):  
Bone Loss ◽  
Effective Treatment ◽  
Kidney Transplant ◽  
Vascular Calcification ◽  
Secondary Osteoporosis ◽  
Control Group ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Mineral Density ◽  
Group A

Kidney transplant recipients develop secondary osteoporosis induced by immunosuppressive medication, with a high risk of fracture, and abdominal aortic calcification (AC) is a known predictor of cardiovascular mortality. In this study of 12 stable kidney recipients, we estimated the preventive effect of bisphosphonate treatment on bone loss and progression of AC. We randomly divided the subjects into a treatment group with alendronate (group A: 5 subjects) and a control group (group C: 7 subjects). Group A patients received 35 mg/week of alendronate over 24 months, while group C patients were not administered with any bisphosphonates. Two major endpoints were established: (1) the time-dependent change in bone mineral density (BMD) estimated with DEXA and (2) progression of abdominal AC, calculated twice as an index (ACI) using computed tomography data. Over the 2-year study period, group A patients showed significantly increased BMD of 1.86 ± 0.85% (P=0.015versus baseline), and almost complete inhibition of ACI progression (38.2 ± 24.2% to 39.6 ± 24.3%), but group C patients showed a decrease in BMD decline with bone loss and progression of ACI (32.8 ± 25.0% to 37.8 ± 29.2%,P=0.061). In conclusion, alendronate therapy was an effective treatment in kidney transplant recipients for secondary osteoporosis and vascular calcification as ectopic calcification. This clinical trial is registered with number JMA-IIA00155 of JMACCT CTR.

Abstract W P250: The Impact of Acute Hypertensive Response on Mortality After Intracerebral Hemorrhage Differs Among Patients With and Without Left Ventricle Hypertrophy

Stroke ◽  
2014 ◽  
Vol 45 (suppl_1) ◽  
Author(s):  
Octavio M Pontes-Neto ◽  
Sergi Martinez-Ramirez ◽  
Anand Viswanathan ◽  
Timothy C Tan ◽  
Maria C Nunes ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Left Ventricle ◽  
Acute Phase ◽  
Blood Pressure Reduction ◽  
Chronic Hypertension ◽  
Pressure Reduction ◽  
Left Ventricle Hypertrophy ◽  
Ventricle Hypertrophy ◽  
Haenszel Test ◽  
Intensive Blood Pressure

Background: While acute hypertensive response (AHR) predicts worse outcome in intracerebral hemorrhage (ICH), the INTERACT-2 trial recently failed to definitively demonstrate a major benefit of intensive blood pressure reduction on these patients. A possible explanation is that the detrimental effect of AHR on outcome may differ among ICH patients with and without previous chronic hypertension. Objective: to explore whether the prognosis of patients with AHR during the acute phase of ICH differs according to the presence or absence of left ventricle hypertrophy (LVH), which is a marker of chronic hypertensive organ damage. Method: we performed a retrospective analysis of a prospective cohort of patients with primary ICH presenting to an academic hospital between January/2000 and December/2012 with age > 18 years, who had a transthoracic echocardiogram available. LVH was defined according to Penn convention. AHR was defined as systolic blood pressure > 180 mmHg on admission. Mantel-Haenszel test was initially used to assess if LVH status influenced the effect of AHR on mortality. For subsequent analyses, ICH patients were divided in 3 groups: without AHR (reference); AHR without LVH; AHR with LVH. A multivariate logistic regression model was then used to identify independent predictors of mortality at 30-days. Results: 430 patients met inclusion criteria. AHR was present in 196 (46.6%), LVH was present in 233 (54.2%); 30-day mortality was 15.6%. On Mantel-Haenszel test, we found a trend (p=0.09) suggesting that absence of LVH increased AHR effect on mortality (OR:1.64; 95% CI: 0.95-2.8; p=0.07). On multivariate analysis, patients with AHR without LVH had significantly higher mortality (OR: 2.65; 95%CI: 1.15 to 6.1; p=0.022) when compared to patients without AHR, after adjusting for baseline characteristics. There was only a trend towards increased mortality in the group of patients with AHR and LVH (OR:2.22; 95% CI: 0.99-5.0; p=0.053). Conclusions: Patients without chronic hypertension appear to be more susceptible to the detrimental effects of AHR during the acute phase of ICH. Stratification of patients with ICH may help to identify those that will have greater benefit with intensive blood pressure reduction in the acute phase of ICH.

scholarly journals ECG-based detection of left ventricle hypertrophy

2015 ◽  
Vol 31 (2) ◽  
pp. 125-132 ◽  
Author(s):  
Gabriel Tozatto Zago ◽  
Rodrigo Varejão Andreão ◽  
Sérgio Lamego Rodrigues ◽  
José Geraldo Mill ◽  
Mário Sarcinelli Filho
Keyword(s):  
Left Ventricle ◽  
Left Ventricle Hypertrophy ◽  
Ventricle Hypertrophy

scholarly journals Longitudinal Mitral Annulus Velocities Are Reduced in Hypertensive Subjects With or Without Left Ventricle Hypertrophy

Hypertension ◽  
2006 ◽  
Vol 47 (5) ◽  
pp. 854-860 ◽  
Author(s):  
Maria Cândida C. Borges ◽  
Roberta C.R. Colombo ◽  
José Geraldo F. Gonçalves ◽  
José de Oliveira Ferreira ◽  
Kleber G. Franchini
Keyword(s):  
Left Ventricle ◽  
Mitral Annulus ◽  
Left Ventricle Hypertrophy ◽  
Ventricle Hypertrophy
Sign in / Sign up

Export Citation Format

Share Document